Division of Urology, Department of Surgery, University of Toronto, Toronto, ON, Canada.
Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada.
Prostate Cancer Prostatic Dis. 2024 Mar;27(1):22-28. doi: 10.1038/s41391-023-00669-z. Epub 2023 Apr 20.
Benign prostatic hyperplasia (BPH) is one of the most common diseases affecting men and can present with bothersome lower urinary tract symptoms (LUTS). Historically, transurethral resection of the prostate (TURP) has been considered the gold standard in the treatment of LUTS due to BPH. However, TURP and other traditional options for the surgical management of LUTS secondary to BPH are associated with high rates of sexual dysfunction. In the past decade, several novel technologies, including Aquablation therapy, convective water vapor therapy (Rezum), and transperineal prostate laser ablation (TPLA), have demonstrated promising evidence to be safe and effective while preserving sexual function.
In this review, we discuss three ablative minimally invasive surgeries: Aquablation, Rezum, and TPLA. We review their techniques, safety, as well as perioperative and functional outcomes. We go into further detail regarding sexual function after these ablative minimally invasive surgical therapies.
Aquablation is a surgeon-guided, robot-executed, heat-free ablative waterjet procedure with sustained functional outcomes at 5 years while having no effect on sexual activity. Rezum is an innovative office-based, minimally invasive surgical option for BPH that delivers convective water vapor energy into prostate adenoma to ablate obstructing tissue. Rezum leads to significant improvements in Qmax, IPSS while preserving sexual function. TPLA is another office-based technology which uses a diode laser source to produce thermoablation. It leads to improvement in Qmax, IPSS, and QoL while preserving ejaculatory function.
Overall, ablative minimally invasive surgical therapies have demonstrated excellent safety and efficacy profiles while preserving sexual function. These modalities should be discussed with patients to ensure informed and shared decision-making. Ablative minimally invasive surgical therapies may be particularly interesting to patients who value the preservation of their sexual function.
良性前列腺增生(BPH)是影响男性的最常见疾病之一,可表现为烦人的下尿路症状(LUTS)。历史上,经尿道前列腺切除术(TURP)被认为是治疗 BPH 所致 LUTS 的金标准。然而,TURP 和其他传统的 BPH 手术治疗方法与性功能障碍的发生率高有关。在过去十年中,几种新型技术,包括 Aquablation 治疗、 convective 水蒸气治疗(Rezum)和经会阴前列腺激光消融术(TPLA),已经证明在保留性功能的同时具有安全性和有效性。
在这篇综述中,我们讨论了三种消融微创手术:Aquablation、Rezum 和 TPLA。我们回顾了它们的技术、安全性以及围手术期和功能结果。我们进一步详细介绍了这些消融微创治疗后对性功能的影响。
Aquablation 是一种由外科医生指导、机器人执行的无热量消融水射流程序,在 5 年内具有持续的功能结果,而对性行为没有影响。Rezum 是一种创新的基于办公室的微创 BPH 治疗选择,它将对流水蒸汽能量输送到前列腺腺瘤中以消融阻塞组织。Rezum 可显著改善 Qmax、IPSS,同时保留性功能。TPLA 是另一种基于办公室的技术,它使用二极管激光源产生热消融。它可改善 Qmax、IPSS 和生活质量,同时保留射精功能。
总的来说,消融微创外科治疗在保留性功能的同时,具有出色的安全性和疗效。应与患者讨论这些方法,以确保做出知情和共同的决策。消融微创外科治疗可能对重视性功能保留的患者特别有吸引力。